Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma

BACKGROUND: Atezolizumab is a treatment for locally advanced/metastatic urothelial carcinoma (mUC). However, its use in patients with renal insufficiency or UC with mixed variant histology (MVH) is not well characterized. OBJECTIVE: To report efficacy and safety of atezolizumab in these special subp...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman-Censits, Jean, Pal, Sumanta, Kaiser, Constanze, Ding, Beiying, Bellmunt, Joaquim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342864/
https://www.ncbi.nlm.nih.gov/pubmed/32641319
http://dx.doi.org/10.1136/jitc-2019-000419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342864/
https://www.ncbi.nlm.nih.gov/pubmed/32641319
http://dx.doi.org/10.1136/jitc-2019-000419

Ejemplares similares